Nexalin Technology is a medical device company that designs and develops neurostimulation products to help combat the ongoing global mental health epidemic. Co. has developed a medical device, referred to as Generation 1, that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Co. has designed and developed new waveform technology to be emitted at 15 milliamps - referred to as Generation 2 which can penetrate deeper into the brain and stimulate associated structures of mental illness. Generation 2 is being tested in pilot trials, for anxiety, insomnia, and depression in the United States. The NXL average annual return since 2022 is shown above.
The Average Annual Return on the NXL average annual return since 2022 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NXL average annual return since 2022 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NXL average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|